Michał Piotr Budzik

Dr. Michał Piotr Budzik

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
OPOlga Partyka
Olga Partyka
MPMonika Pajewska
Monika Pajewska
DKDaria Kwaśniewska
Daria Kwaśniewska
ACAleksandra Czerw
Aleksandra Czerw
ADAndrzej Deptała
Andrzej Deptała
Remigiusz KozlowskiRemigiusz Kozlowski
Remigiusz Kozlowski
Pancreatic cancer is the seventh most common cause of death in the group of oncological diseases. Due to the asymptomatic course, early diagnosis is difficult. Currently, early detection methods are only used in high-risk groups. A literature review based on the available results of observational studies on patients with pancreatic cancer and people from high-risk groups was used to summarize the knowledge on risk factors. The GLOBOCAN 2020 data were used to assess the epidemiological situation in Europe. A summary of screening recommendations was prepared based on the available documents from medical organizations and associations. Pancreatic cancer risk factors are divided into two main groups: non-modifiable factors, e.g., hereditary factors and age, which increase the risk of developing this disease, and modifiable factors—BMI, smoking, and alcohol consumption. Hereditary factors account for 10% of pancreatic cancer cases. The highly specialized methods of early detection, (MRI, CT, or EUS) are used for screening high-risk populations. Of all the imaging methods, EUS is considered the most sensitive for pancreatic cancer and allows an accurate assessment of the size of even small lesions (<30 mm) and the extent of tumour infiltration into blood vessels. The available studies vary on the level of sensitivity and specificity of these methods for the diagnosis of pancreatic cancer. EUS, MRI, and CT are also expensive procedures and in some patients can be invasive, which is one of the arguments against the introduction of population screening programs based on imaging methods. Therefore, it is important to look for viable solutions that would improve early detection. This is important from the point of view of healthcare systems in Europe, where almost 29% of all global pancreatic cancer cases are reported.

22 February 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
EWEmilia Włoszek
Emilia Włoszek
KKKamila Maria Krupa
Kamila Maria Krupa
ESEliza Skrok
Eliza Skrok
MBMichał Piotr Budzik
Michał Piotr Budzik
ADAndrzej Deptała
Andrzej Deptała
ABAnna Badowska-Kozakiewicz
Anna Badowska-Kozakiewicz
One of the most significant breakthroughs in cancer research has been the identification of persistent infection with certain human papillomaviruses (HPV) genotypes as the cause of cervical cancer. Since then, a range of diagnostic and therapeutic methods has been developed based on this discovery. This article aims to describe the latest updates in the biology, prevention, and treatment of HPV-related cervical cancer. The current state of knowledge regarding vaccinations, diagnostic tests, and cervical cancer therapies is presented. The latest WHO guidelines on vaccinations are presented, as well as announcements of upcoming changes. The final part of the article summarizes promising new diagnostic and treatment methods, as well as perspectives and the latest research findings on self-administered diagnostic tests, the use of therapeutic vaccines, and circulating cell-free DNA in diagnosis. Despite the significant progress made in recent years, the strategy based on vaccination and testing remains the cornerstone in the fight against HPV-related cervical cancer.

11 March 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MBMichał Piotr Budzik
Michał Piotr Budzik
MFMarta Magdalena Fudalej
Marta Magdalena Fudalej
ABAnna Maria Badowska-Kozakiewicz
Anna Maria Badowska-Kozakiewicz
Mucinous breast cancer (MBC) is a rare histological type of breast cancer characterized primarily by mucin's production and extracellular presence. MBC is usually associated with a better prognosis than other invasive breast neoplasms. Because of the low prevalence, MBC biology is not well understood. The aim of the present study was to introduce the last 2-year experience regarding MBC pathological diagnostics in our clinical center and comparison of the obtained data with invasive breast carcinoma of no special type (NST) comprising the most common invasive breast cancer. We identified 24 MBC cases representing 3.09% of all 766 invasive breast cancers, including 15 cases of pure type and 9 mixed MBCs. The median MBC patients' age at presentation was 65.5 years. Compared to NST, MBC presented a higher T stage with a statistically larger tumor median size, although lower regional lymph node involvement, tumor histological grade and TNM stage. MBC is a rare type of breast cancer, accounting for about 4% of all diagnosed breast cancers. Our findings are consistent with those published in recent years and show significant differences between MBC and NST cancer patients and also highlight differences between pure and mixed MBC, emphasizing the essence of their differentiation. MBC is associated with a better long-term prognosis than NST and is characterized by the less aggressive biological behavior expressed through favorable clinicopathologic features in terms of tumor grade, regional lymph node involvement and hormone receptor status.

1 January 2016 in Contemporary Oncology
Verified
Journal Article
Open access
ABAnna Badowska-Kozakiewicz
Anna Badowska-Kozakiewicz
MBMichał Piotr Budzik
Michał Piotr Budzik
Basal-like breast cancer (BLBC) occurs mainly in young patients. It is characterized by an aggressive clinical outcome, presence of distant metastases, particularly within the first five years of the disease, bad prognosis and relatively high mortality. Recently greater interest of scientists in...

Verified
Journal Article
Open access
PDF file
ONOlga Niwczyk
Olga Niwczyk
MGMonika Grymowicz
Monika Grymowicz
ASAleksandra Szczęsnowicz
Aleksandra Szczęsnowicz
MHMarta Hajbos
Marta Hajbos
AKAnna Kostrzak
Anna Kostrzak
Blazej MeczekalskiBlazej Meczekalski
Blazej Meczekalski
The bony skeleton, as a structural foundation for the human body, is essential in providing mechanical function and movement. The human skeleton is a highly specialized and dynamic organ that undergoes continuous remodeling as it adapts to the demands of its environment. Advances in research over the last decade have shone light on the various hormones that influence this process, modulating the metabolism and structural integrity of bone. More recently, novel and non-traditional functions of hypothalamic, pituitary, and adipose hormones and their effects on bone homeostasis have been proposed. This review highlights recent work on physiological bone remodeling and discusses our knowledge, as it currently stands, on the systemic interplay of factors regulating this interaction. In this review, we provide a summary of the literature on the relationship between bone physiology and hormones including kisspeptin, neuropeptide Y, follicle-stimulating hormone (FSH), prolactin (PRL), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), growth hormone (GH), leptin, and adiponectin. The discovery and understanding of this new functionality unveils an entirely new layer of physiologic circuitry.

1 February 2019 in The Breast
Verified
Journal Article
Closed access
MBMichał Piotr Budzik
Michał Piotr Budzik
JPJ. Patera
J. Patera
MSM. Sobol
M. Sobol
ACAleksandra Czerw
Aleksandra Czerw
ADA. Deptała
A. Deptała
ABA.M. Badowska-Kozakiewicz
A.M. Badowska-Kozakiewicz